Impact of Common Iliac Nodal Treatment on Radiation Outcomes in Localized Prostate Cancer

Urology

Volumn 71, Issue 2, 2008, Pages 313-317

  Soto, Daniel E ^a   Glaser, Scott ^a   Roberts, Rebecca H ^a   Schipper, Matthew J ^a   McLaughlin, Patrick W ^a   Ray, Michael E ^a   Sandler, Howard M ^a   Pan, Charlie C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

AGED; HUMANS; LYMPH NODES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 39549095601     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.08.037     Document Type: Article

References (30)

1. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
2. Stephenson A.J., and Kattan M.W. Nomograms for prostate cancer. BJU Int 98 (2006) 39-46
3. Roach III M., Marquez C., Yuo H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994) 33-37
4. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
5. Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls?. An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 1355-1359
6. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
7. Scalliet P., Renard L., Lengelé B., et al. CTV for lymphatics in prostate adenocarcinoma, an anatomical description and a clinical discussion. In: Gregoire V., Scalliet P., and Ang K.K. (Eds). Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy: A Clinical Guide to Cancer Treatment (2004), Springer, New York 145-156
8. Jackson A.S., Sohaib S.A., Staffurth J.N., et al. Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy. Clin Oncol (R Coll Radiol) 18 (2006) 109-116
9. Seaward S.A., Weinberg V., Lewis P., et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 1055-1062
10. Perez C.A., Michalski J., Brown K.C., et al. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 36 (1996) 573-584
11. Rasp G., Piansky T., Haddock M., et al. Elective pelvic nodal irradiation in patients with clinically localized prostate cancer at high risk for pelvic nodal involvement. ASTRO 36 (1996) 245
12. Horwitz E.M., Hanlon A.L., Pinover W.H., et al. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 41 (1998) 519-523
13. Jacob R., Hanlon A.L., Horwitz E.M., et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 61 (2005) 695-701
14. Vargas C.E., Galalae R., Demanes J., et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 63 (2005) 1474-1482
15. Pan C.C., Kim K.Y., Taylor J.M., et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53 (2002) 1139-1145
16. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
17. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
18. Roach III M., Desilvio M., Valicenti R., et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66 (2006) 647-653
19. Luxton G., Hancock S.L., and Boyer A.L. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 59 (2004) 267-284
20. Ashman J.B., Zelefsky M.J., Hunt M.S., et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 765-771
21. Mundt A.J., Lujan A.E., Rotmensch J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 52 (2002) 1330-1337
22. Wang-Chesebro A., Coleman J., Xia P., et al. IMRT improves pelvic lymph node (PLN) coverage and dose to critical structures compared with standard four field (4F) whole pelvis (WP) radiation therapy (RT) in prostate cancer (PC). ASTRO 63 (2005) S194
23. Jani A.B., Su A., and Milano M.T. Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity. Urology 67 (2006) 147-151
24. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
25. Shih H.A., Harisinghani M., Zietman A.L., et al. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 63 (2005) 1262-1269
26. Ganswindt U., Paulsen F., Corvin S., et al. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer 5 (2005) 91-104
27. Dinniwell R., Chan P., Haider M., et al. Magnetic resonance lymphography with ferumoxtran-10 for pelvic lymph node target delineation in bladder and prostate cancer. ASTRO 63 (2005) S193
28. Taylor A., Rockall A.G., Reznek R.H., et al. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 1604-1612
29. van den Berg H.A., Olofsen-van Acht M.J., van Santvoort J.P., et al. Definition and validation of a reference target volume in early stage node-positive cervical carcinoma, based on lymphangiograms and CT-scans. Radiother Oncol 54 (2000) 163-170
30. Chao K.S., and Lin M. Lymphangiogram-assisted lymph node target delineation for patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 54 (2002) 1147-1152